Literature DB >> 20667520

Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Oliver Bruder1, Anja Wagner, Christoph J Jensen, Steffen Schneider, Peter Ong, Eva-Maria Kispert, Kai Nassenstein, Thomas Schlosser, Georg V Sabin, Udo Sechtem, Heiko Mahrholdt.   

Abstract

OBJECTIVES: We sought to establish the prognostic value of a comprehensive cardiovascular magnetic resonance (CMR) examination in risk stratification of hypertrophic cardiomyopathy (HCM) patients.
BACKGROUND: With annual mortality rates ranging between 1% and 5%, depending on patient selection, a small but significant number of HCM patients are at risk for an adverse event. Therefore, the identification of and prophylactic therapy (i.e., defibrillator placement) in patients with HCM who are at risk of dying are imperative.
METHODS: Two-hundred forty-three consecutive patients with HCM were prospectively enrolled. All patients underwent initial CMR, and 220 were available for clinical follow-up. The mean follow-up time was 1,090 days after CMR. End points were all-cause and cardiac mortality.
RESULTS: During follow-up 20 of the 220 patients died, and 2 patients survived sudden cardiac death due to adequate implantable cardioverter-defibrillator discharge. Most events (n = 16) occurred for cardiac reasons; the remaining 6 events were related to cancer and accidents. Our data indicate that the presence of scar visualized by CMR yields an odds ratio of 5.47 for all-cause mortality and of 8.01 for cardiac mortality. This might be superior to classic clinical risk factors, because in our dataset the presence of 2 risk factors yields an odds ratio of 3.86 for all-cause and of 2.20 for cardiac mortality, respectively. Multivariable analysis also revealed the presence of late gadolinium enhancement as a good independent predictor of death in HCM patients.
CONCLUSIONS: Among our population of largely low or asymptomatic HCM patients, the presence of scar indicated by CMR is a good independent predictor of all-cause and cardiac mortality.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20667520     DOI: 10.1016/j.jacc.2010.05.007

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  164 in total

1.  MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors.

Authors:  Yasuo Amano; Mitsunobu Kitamura; Morimasa Takayama; Masaki Tachi; Shinichiro Kumita
Journal:  Int J Cardiovasc Imaging       Date:  2012-03-04       Impact factor: 2.357

Review 2.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

3.  Cardiomyopathies: Myocardial fibrosis assessed by CMR to predict events in HCM.

Authors:  Nina Ajmone Marsan; Jeroen J Bax
Journal:  Nat Rev Cardiol       Date:  2010-11       Impact factor: 32.419

Review 4.  The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy.

Authors:  Mouaz H Al-Mallah; Mohammad Naseem Shareef
Journal:  Heart Fail Rev       Date:  2011-07       Impact factor: 4.214

5.  The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation .

Authors:  Tomas G Neilan; Ravi V Shah; Siddique A Abbasi; Hoshang Farhad; John D Groarke; John A Dodson; Otavio Coelho-Filho; Ciaran J McMullan; Bobak Heydari; Gregory F Michaud; Roy M John; Rob van der Geest; Michael L Steigner; Ron Blankstein; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  J Am Coll Cardiol       Date:  2013-08-28       Impact factor: 24.094

Review 6.  The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Authors:  Julian G Westphal; Angelos G Rigopoulos; Constantinos Bakogiannis; Sarah E Ludwig; Sophie Mavrogeni; Boris Bigalke; Torsten Doenst; Matthias Pauschinger; Carsten Tschöpe; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 7.  Heart failure in patients with normal coronary anatomy: diagnostic algorithm and disease pattern of various etiologies as defined by cardiac MRI.

Authors:  Ralf Wassmuth
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

8.  T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy.

Authors:  Christopher T Sibley; Radwa A Noureldin; Neville Gai; Marcelo Souto Nacif; Songtao Liu; Evrim B Turkbey; James O Mudd; Rob J van der Geest; João A C Lima; Marc K Halushka; David A Bluemke
Journal:  Radiology       Date:  2012-10-22       Impact factor: 11.105

9.  Effects of hypertrophy and fibrosis on regional and global functional heterogeneity in hypertrophic cardiomyopathy.

Authors:  Sung-A Chang; Sang-Chol Lee; Yeon Hyeon Choe; Hye-Jin Hahn; Shin Yi Jang; Sung-Ji Park; Jin-Oh Choi; Seung Woo Park; Jae K Oh
Journal:  Int J Cardiovasc Imaging       Date:  2012-10-25       Impact factor: 2.357

10.  High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy.

Authors:  Yasuki Hen; Nobuo Iguchi; Haruhiko Machida; Kaori Takada; Yuko Utanohara; Tetsuya Sumiyoshi
Journal:  Heart Vessels       Date:  2012-10-25       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.